Cosentyx

Chemical Namesecukinumab
Dosage FormInjection (subcutaneous; 150 mg/mL)
Drug ClassMonoclonal antibodies
SystemSkin, Musculoskeletal
CompanyNovartis
Approval Year2015

Indication

  • To treat moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
  • For adults with active psoriatic arthritis (PsA).
  • For adults with active ankylosing spondylitis (AS).
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cosentyx (secukinumab) Prescribing Information2020Novartis Pharmaceuticals Corporation, East Hanover, NJ